Corporate ActionOct 30, 2026, 05:16 PM
Rapport Therapeutics Prices $215.7M Public Offering of Stock and Warrants
AI Summary
Rapport Therapeutics, Inc. announced the closing of an underwritten public offering of common stock and pre-funded warrants. The offering, which included the exercise of the underwriters' option, is expected to yield approximately $215.7 million in net proceeds. These funds are earmarked for advancing clinical trials for RAP-219, other research and development activities, and general corporate purposes, with the company projecting operational funding through the end of 2029.
Key Highlights
- Rapport Therapeutics priced an underwritten public offering of 8,333,334 shares of common stock at $21.00 per share.
- The company also offered pre-funded warrants to purchase up to 1,190,476 shares of common stock at $20.999 per warrant.
- Underwriters exercised their option to purchase an additional 1,428,571 shares of common stock.
- The offering is expected to generate approximately $215.7 million in net proceeds.
- Proceeds will fund clinical trials for RAP-219, R&D, and general corporate purposes.
- The company anticipates funding operations through the end of 2029 with these proceeds and existing cash.
Price Impact
More from RAPP